New benchmark: 1 kg of plasmid DNA manufactured

Kaneka Eurogentec sets new benchmark in plasmid DNA manufacturing with the production of 1 kg of plasmid DNA.

Image Credit: Kaneka Eurogentec

Attractive cost of goods gives plasmid DNA commercial path forward and positions Kaneka Eurogentec as the premier supplier for plasmid DNA.

Kaneka Eurogentec, an FDA inspected CDMO focused on the production of injectable grade cGMP biopharmaceuticals, announced the manufacture of 1 kg of plasmid DNA, in a single batch, for a major drug development company.

The achievement is remarkable for its efficiency in producing 1 kilogram of plasmid DNA from a single fermentation run. The product quality was confirmed to be above the customer’s specifications and greenlights the commercial supply potential of Kaneka Eurogentec’s cGMP production capability.

Key accomplishments:

  • Scale-up of fermentation, lysis and purification technology to kg-scale as a single batch
  • Active form of product purified higher than customer’s target specification
  • Reduction of supply costs by minimizing purification to a single chromatography step to purify all the plasmid material

This successful production opens commercial opportunities for plasmid DNA drug development companies, both in the field of DNA vaccines and non-viral gene therapy. The efficiency of the production platform changes the economics of launching a plasmid DNA based drug.”

Lieven Janssens, CEO, Kaneka Eurogentec

About plasmid DNA

Plasmid DNA has significant potential for:

  • Non-viral gene therapy by delivering specific genes into patient’s cells
  • Vaccination by introducing the necessary DNA sequence for antigen production and triggering the necessary humoral and cellular immune response.
  • Cancer therapy by delivering cytokines that stimulate the immune system to attack cancer cells, inhibit tumor growth or induce apoptosis in cancer cells.
  • Use as a starting material for viral vector and mRNA based therapies.

All plasmid DNA benefit from rapid design, an excellent safety profile, thermal stability and platform manufacturing. The ability to manufacture plasmid DNA at large scale further enhances its potential for clinical advancement and commercial supply.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kaneka Eurogentec S.A. (2024, August 28). New benchmark: 1 kg of plasmid DNA manufactured. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20240827/New-benchmark-1-kg-of-plasmid-DNA-manufactured.aspx.

  • MLA

    Kaneka Eurogentec S.A. "New benchmark: 1 kg of plasmid DNA manufactured". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20240827/New-benchmark-1-kg-of-plasmid-DNA-manufactured.aspx>.

  • Chicago

    Kaneka Eurogentec S.A. "New benchmark: 1 kg of plasmid DNA manufactured". News-Medical. https://www.news-medical.net/news/20240827/New-benchmark-1-kg-of-plasmid-DNA-manufactured.aspx. (accessed October 11, 2024).

  • Harvard

    Kaneka Eurogentec S.A. 2024. New benchmark: 1 kg of plasmid DNA manufactured. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20240827/New-benchmark-1-kg-of-plasmid-DNA-manufactured.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.